Sham Mailankody, MBBS
Myeloma Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Plasma Cell Disorders (Myeloma, Monoclonal Gammopathies, and Amyloidosis)
Request an Appointment
About Me
- Clinical Director, Cellular Therapy Service
- Research Director, Myeloma Service
I am a medical oncologist specializing in the care of people with multiple myeloma and related plasma cell disorders. With my colleagues at Memorial Sloan Kettering Cancer Center (MSK), I am focused on identifying optimal treatment strategies for people with these disorders.
My research focuses on the development of novel immune and cellular therapies, including chimeric antigen receptor (CAR) T cell therapies, for patients with myeloma. I also serve as the Clinical Director of the Cellular Therapy Service and the Research Director of the Myeloma Service at MSK.
A myeloma specialist is a doctor with special training in diagnosing and treating myeloma.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Plasma Cell Disorders (Myeloma, Monoclonal Gammopathies, and Amyloidosis)
Education
- MBBS, K.S. Hegde Medical Academy
Residencies
- Internal Medicine - Georgetown University/Washington Hospital Center
Fellowships
- Medical Oncology - National Cancer Institute
Board Certifications
- Medical Oncology
- Internal Medicine
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Mailankody sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Mailankody
- A Phase 1 Study of BMS-986393 CAR T Cell Therapy in People With Multiple Myeloma
- A Phase 1 Study of BMS-986453 CAR T Cell Therapy in People With Multiple Myeloma
- A Phase 1 Study of CB-011 CAR T Cell Therapy in People With Multiple Myeloma
- A Phase I Study of MCARH109 and MCARH125 CAR T-Cell Therapy in People with Multiple Myeloma
Read more
- A Study of Talquetamab for People With Multiple Myeloma Who Had CAR T Cell Therapy
- Clinical Trials Co-Investigated by Dr. Mailankody
- A Phase 1 Study of Elranatamab With Iberdomide in People With Multiple Myeloma
- A Phase 1 Study of JNJ-79635322 in People With Multiple Myeloma or AL Amyloidosis
- A Phase 1 Study of KTX-1001 in People With Multiple Myeloma
- A Phase 1b Study of Elranatamab Plus Carfilzomib and Dexamethasone or Elranatamab Plus PF-07901801 in People With Multiple Myeloma
- A Phase 1b/2 Study of Talquetamab and Teclistamab in People With Multiple Myeloma
- A Phase 2 Study of Leflunomide in African-American and European-American People with High-Risk Smoldering Multiple Myeloma
- A Phase I/II Study of Cevostamab Immunotherapy in People with Multiple Myeloma
- A Phase IB Study of Belantamab Mafodotin and Nirogacestat in People with Persistent Multiple Myeloma
- A Phase II Study of JNJ-68284528 CAR T-Cell Therapy to Treat Multiple Myeloma
- A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
- Access to Belantamab Mafodotin for People with Multiple Myeloma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Mailankody’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sham Mailankody discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Arcellx, Inc.
Professional Services and Activities -
Bio Ascend
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
British Association of Cancer Research
Professional Services and Activities -
Cigna Corporation
Professional Services and Activities -
EcoR1 Capital LLC
Professional Services and Activities -
Elsevier
Professional Services and Activities -
Evicore
Professional Services and Activities -
Galapagos NV
Professional Services and Activities
-
Intellisphere, LLC
Professional Services and Activities -
Janssen Oncology, Inc.
Professional Services and Activities -
Legend Biotech USA Inc.
Professional Services and Activities -
MD Education Ltd
Professional Services and Activities -
MJH Life Sciences
Professional Services and Activities -
ONK Therapeutics, Ltd.
Professional Services and Activities -
OptumHealth Care Solutions, LLC
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
Plexus Communications
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].